Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NFX-21
- Development stage
- Unknown
- Lead developer
- Nectid
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
NFX-21 is a small molecule drug under development by Nectid, Inc. It acts as a modulator of the farnesoid X receptor (FXR), also known as the bile acid receptor. FXR modulators are being investigated for their potential to treat diseases related to bile acid metabolism and liver function. The primary indication for NFX-21 is nonalcoholic steatohepatitis (NASH), a progressive liver disease characterized by fat accumulation, inflammation, and damage in the liver not caused by alcohol use. As of June 2025, NFX-21 has reached clinical phase development but has not received regulatory approval in any major market[1][2][3].
02
Targets
FXR (Farnesoid x-activated receptor)
Beyond the preview
Go deeper on NFX-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NFX-21.